Cytek Biosciences (NASDAQ:CTKB) Posts Quarterly Earnings Results, Hits Expectations

Cytek Biosciences (NASDAQ:CTKB) announced its earnings results on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09), FiscalAI reports. Cytek Biosciences had a negative net margin of 36.25% and a negative return on equity of 10.07%. The business had revenue of $48.14 million for the quarter, compared to analyst estimates of $47.31 million.

Here are the key takeaways from Cytek Biosciences’ conference call:

• Q2 revenue increased 6% year over year to $48.1 million, driven by 18% growth in the U.S., strong double-digit growth in China, high-end FSP instrument sales, and continued service momentum. Management raised the low end of full-year 2026 revenue guidance to $207 million-$212 million.
• Recurring revenue continued to strengthen, with service revenue up 10% to $15.6 million and combined reagents and service revenue representing 35% of trailing-12-month revenue. Cytek expects adjusted EBITDA to improve in the second half and reach approximately breakeven for full-year 2026.
• Cytek launched the Borealis, a 60-color, seven-laser full spectral-flow cytometer, and expanded Aurora Evo automation capabilities for biopharma and CRO laboratories. Management said early customer feedback on Borealis has been strong and believes the products can support future market-share gains.
• Regional and profitability pressures persisted: EMEA revenue declined approximately 8% amid government budget constraints, while GAAP net loss widened to $12.2 million from $5.6 million a year earlier. Operating expenses rose 15%, including higher legal costs tied to patent litigation and increased personnel expenses.
• The company began reorganizing into three customer-aligned business units—Solutions and Clinical, Research Technology, and Service—aiming to improve market penetration and growth, particularly in mid- and low-end instruments, reagents, and clinical applications. Management said the benefits will take time to materialize and are already incorporated into 2026 guidance.

Cytek Biosciences Stock Performance

Cytek Biosciences stock traded down $0.10 during midday trading on Wednesday, reaching $4.18. The stock had a trading volume of 993,945 shares, compared to its average volume of 751,687. The stock’s 50-day simple moving average is $4.31 and its 200 day simple moving average is $4.42. Cytek Biosciences has a twelve month low of $3.28 and a twelve month high of $6.18. The stock has a market capitalization of $539.81 million, a PE ratio of -7.33 and a beta of 1.17.

Hedge Funds Weigh In On Cytek Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Federated Hermes Inc. raised its holdings in Cytek Biosciences by 150.9% in the second quarter. Federated Hermes Inc. now owns 7,221 shares of the company’s stock valued at $25,000 after buying an additional 4,343 shares during the period. Captrust Financial Advisors purchased a new stake in Cytek Biosciences during the second quarter worth approximately $43,000. CIBC Bancorp USA Inc. purchased a new stake in Cytek Biosciences during the third quarter worth approximately $43,000. Tower Research Capital LLC TRC increased its position in shares of Cytek Biosciences by 338.1% in the second quarter. Tower Research Capital LLC TRC now owns 19,760 shares of the company’s stock worth $67,000 after acquiring an additional 15,250 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in shares of Cytek Biosciences in the third quarter worth $75,000. 69.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have issued reports on CTKB shares. Stephens dropped their target price on Cytek Biosciences from $5.50 to $4.75 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cytek Biosciences in a research note on Wednesday, June 24th. Finally, Morgan Stanley lowered their target price on shares of Cytek Biosciences from $6.00 to $5.50 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Cytek Biosciences presently has an average rating of “Hold” and a consensus price target of $5.69.

Cytek Biosciences Company Profile

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.